


Our Pipeline

We are building a pipeline of *in vivo* and *ex vivo* therapies, as well as continuing to develop innovative modular platform capabilities.

Program	Approach	Research	Candidate Selection	IND-Enabling	Early-Stage Clinical	Late-Stage Clinical	
In Vivo: CRISPR <u>is</u> the therapy							
NTLA-2001: Transthyretin Amyloidosis	Knockout						LEAD Intellia [®] THERAPEUTICS * REGENERON
NTLA-2002: Hereditary Angioedema	Knockout						Intellia [®] THERAPEUTICS
Hemophilia A and B	Insertion						LEAD REGENERON * Intellia [®] THERAPEUTICS
Research Programs	Knockout, Insertion, Consecutive Edits						Intellia [®] THERAPEUTICS
Research Programs	Various						Intellia [®] THERAPEUTICS REGENERON**
Ex Vivo: CRISPR <u>creates</u> the therapy							
OTQ923 / HIX763: Sickle Cell Disease	HSC						NOVARTIS Intellia [®] THERAPEUTICS ***
NTLA-5001: Acute Myeloid Leukemia	WT1-TCR						Intellia [®] THERAPEUTICS
Solid Tumors	WT1-TCR						Intellia [®] THERAPEUTICS
Allo Undisclosed	Undisclosed						Intellia [®] THERAPEUTICS
Other Novartis Programs	CAR-T, HSC, OSC	Undisclosed					NOVARTIS Intellia [®] THERAPEUTICS ***



* Lead development and commercial party
CAR-T: Chimeric Antigen Receptor T cells

** Rights to certain *in vivo* targets
HSC: Hematopoietic Stem Cells

*** Milestones & royalties
OSC: Ocular Stem Cells

Updated June 22, 2021

